Impel Pharmaceuticals Inc. announced on April 10, 2023, H. Stewart Parker advised the board of directors (the board) of the company that she would resign as a Class I director of the board, effective on April 10, 2023. Ms. Parker's resignation is not the result of any disagreement with the company on any matter relating to its operations, policies or practices. On April 12, 2023, the board appointed Darren Cline as a Class I director and as a member of the Nominating and Corporate Governance Committee, effective immediately.

From March 2022 to March 2023, Mr. Cline served as Chief Executive Officer and President of Epygenix Therapeutics. From April 2019 to May 2021, Mr. Cline served as the U.S. Chief Commercial Officer and member of the Executive Committee for Greenwich Bioscience, the U.S. subsidiary of GW Pharmaceuticals prior to its acquisition by Jazz Pharmaceuticals for $7.2 Billion. From October 2010 to March 2019, Mr. Cline served in various roles at Seagen Inc. (formerly Seattle Genetics Inc.), including as its Executive Vice President, Commercial, Senior Vice-President, Commercial, and Vice President, Managed Markets, where he oversaw all marketing, sales, and managed markets.

He was directly involved in the commercial build out for the launch of Adcetris, an antibody-drug conjugate (ADC) the U.S. Food and Drug Administration approved for treatment of certain hematologic cancers and played an integral role driving Adcetris's continued growth. Mr. Cline also held numerous commercial leadership roles at Alexion. Intermune and Amgen.

Mr. Cline is also currently a non-executive director of Pyxis Oncology Inc., a preclinical oncology company focused on developing next-generation therapeutics to target difficult-to-treat cancers. Mr. Cline is also currently a non-executive director for Pliant Therapeutics, a clinical stage company focused on discovering, developing and commercializing breakthrough treatments for fibrotic diseases. From 2018 to 2020, Mr. Cline served as a non-executive director of Stemline Therapeutics Inc., a commercial-stage biopharmaceutical company focused on the development and commercialization of novel oncology therapeutics prior to the acquisition by the Menarini Group.

Mr. Cline holds a B.S. from San Diego State University and an M.B.A. from Pepperdine University.